Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs
Lin Xu, Xu Che · 2024
Read Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs by Lin Xu, Xu Che (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646846.txt.
Description
Lin Xu and Xu Che test a two-drug first-line combo for liver cancer that cannot be removed, and ask whether circulating tumor cells predict who benefits. The pairing joins sorafenib with the antibody tislelizumab. Blood-borne tumor cells may carry useful warning signals.
Thirty-two patients with advanced liver cancer enrolled. The antibody was infused every three weeks on schedule. Sorafenib tablets were taken twice daily at home. Scans every nine weeks judged tumor response. Cell counts and a surface marker were measured at entry. Safety and response formed the main readouts. Marker levels were tied to patient prognosis afterward. The study hunts a cheap blood test for guidance.
Catalog record
| CREATOR | Lin Xu, Xu Che |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |